Literature DB >> 15860303

Recurrent retinal angiomatous proliferation after surgical ablation.

Susumu Sakimoto1, Fumi Gomi, Hirokazu Sakaguchi, Yasuo Tano.   

Abstract

PURPOSE: To report a case of retinal angiomatous proliferation (RAP) treated by ablation of the feeding and draining vessels that recurred by 6 months postoperatively.
DESIGN: Interventional case report.
METHODS: Images from fluorescein angiography, indocyanine green (ICG) angiography, and optical coherence tomography (OCT) were examined before and after ablation.
RESULTS: The hot spot on late-phase ICG, the leakage on fluorescein angiography, the pigment epithelial detachment, and macular edema on OCT decreased postoperatively. However, a large hyperfluorescent lesion was detected on ICG 6 months postoperatively with recurrent cystoid macular edema.
CONCLUSIONS: A new RAP lesion can develop even after the original lesion seemed to resolve after ablation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15860303     DOI: 10.1016/j.ajo.2004.10.046

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  11 in total

1.  Treatment of recurrent retinal angiomatous proliferation with intravitreal triamcinolone acetonide followed by photodynamic therapy with verteporfin: A retrospective case series.

Authors:  Nicola Cardascia; Claudio Furino; Andrea Ferrara; Francesco Boscia; Giovanni Alessio
Journal:  Curr Ther Res Clin Exp       Date:  2009-06

2.  [Intravitreal ranibizumab for the treatment of retinal angiomatous proliferation].

Authors:  J Maaß; D Sandner; E Matthé
Journal:  Ophthalmologe       Date:  2017-06       Impact factor: 1.059

3.  Intravitreal triamcinolone and laser photocoagulation for retinal angiomatous proliferation.

Authors:  T R Krieglstein; A Kampik; M Ulbig
Journal:  Br J Ophthalmol       Date:  2006-08-02       Impact factor: 4.638

4.  Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano; Kanako Itagaki
Journal:  Jpn J Ophthalmol       Date:  2016-01       Impact factor: 2.447

5.  Retinal angiomatous proliferation associated with risk alleles of ARMS2/HTRA1 gene polymorphisms in Japanese patients.

Authors:  Yasuhiro Ohkuma; Takaaki Hayashi; Tsutomu Sakai; Akira Watanabe; Hisashi Yamada; Masakazu Akahori; Takeshi Itabashi; Takeshi Iwata; Toru Noda; Hiroshi Tsuneoka
Journal:  Clin Ophthalmol       Date:  2013-12-27

6.  One year results of intravitreal ranibizumab monotherapy for retinal angiomatous proliferation: a comparative analysis based on disease stages.

Authors:  Young Gun Park; Young-Jung Roh
Journal:  BMC Ophthalmol       Date:  2015-12-21       Impact factor: 2.209

7.  Short-term efficacy of intravitreal Aflibercept injections for retinal angiomatous proliferation.

Authors:  Hung-Da Chou; Wei-Chi Wu; Nan-Kai Wang; Lan-Hsin Chuang; Kuan-Jen Chen; Chi-Chun Lai
Journal:  BMC Ophthalmol       Date:  2017-06-27       Impact factor: 2.209

8.  Observation of treated iris neovascularization by swept-source-based en-face anterior-segment optical coherence tomography angiography.

Authors:  Daiki Shiozaki; Susumu Sakimoto; Akihiko Shiraki; Taku Wakabayashi; Yoko Fukushima; Yoshinori Oie; Shinichi Usui; Shigeru Sato; Hirokazu Sakaguchi; Kohji Nishida
Journal:  Sci Rep       Date:  2019-07-16       Impact factor: 4.379

9.  Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation.

Authors:  Maiko Maruyama-Inoue; Shimpei Sato; Shin Yamane; Kazuaki Kadonosono
Journal:  Clin Ophthalmol       Date:  2019-10-08

Review 10.  Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration.

Authors:  Paris Tranos; Athanasios Vacalis; Solon Asteriadis; Stavrenia Koukoula; Athanasios Vachtsevanos; Georgia Perganta; Ilias Georgalas
Journal:  Drug Des Devel Ther       Date:  2013-06-17       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.